AZCERT

AZCERT participates in multi-stakeholder collaborations to develop and disseminate clinical decision support programs, such as for QTc Risk Score, to enhance medication safety.

AZCERT participates in multi-stakeholder collaborations to develop and disseminate clinical decision support programs, such as for QTc Risk Score, to enhance medication safety.

Performs active and passive surveillance of thousands of prescription drugs in the U.S. to assess QT prolongation risk and inform updates to the QTdrugs List.

Performs active and passive surveillance of thousands of prescription drugs available in the U.S. to assess associations with QT prolongation, using scientific literature, case reports, label changes, and clinical studies to inform safety evaluations.

Authors peer-reviewed articles and expert opinions on drug safety, cardiovascular pharmacology, and regulatory science in journals such as Nature Reviews of Cardiology and Annual Review of Pharmacology and Toxicology. Topics include QT prolongation, drug regulation history, and medication risk assessment.

Regularly evaluates and updates the QTdrugs List and the List of Drugs to Avoid in patients with Congenital Long QT Syndrome (cLQTS) based on scientific evidence reviewed by AZCERT's Scientific Review Committee. Updates include adding, removing, or reclassifying drugs according to their risk of QT prolongation and torsades de pointes (TdP).

Regularly evaluates and updates the QTdrugs List and the List of Drugs to Avoid in patients with Congenital Long QT Syndrome (cLQTS) based on scientific evidence reviewed by AZCERT's Scientific Review Committee. This includes adding, removing, or reclassifying drugs according to their risk of QT prolongation and torsades de pointes (TdP).

Designs, validates, and disseminates MedSafetyScan, an online QT/torsades de pointes patient risk assessment tool. The tool’s risk score model has been scientifically validated in psychiatric inpatient populations and through multi-stakeholder collaborations to support clinical decision-making.

Designs, validates, and disseminates MedSafetyScan, an online QT/torsades de pointes patient risk assessment tool. The tool’s risk score model has been validated in peer-reviewed studies, including in psychiatric inpatient populations, and was developed through multi-stakeholder collaboration.

AZCERT developed and validated MedSafetyScan, an online tool for assessing patient risk of QT prolongation and torsades de pointes, with its efficacy and accuracy confirmed through scientific studies in psychiatric inpatient populations.

AZCERT developed and validated MedSafetyScan, an online tool for assessing patient risk of QT/torsades de pointes, with its efficacy and accuracy confirmed through scientific studies in psychiatric inpatient populations.

AZCERT's Scientific Review Committee evaluates specific drugs, such as Opipramol, Revumenib, Sitafloxacin, Bilastine, Gepotidacin, Dordaviprone, Triclabendazole, Ziftomenib, Milsaperidone, Cinacalcet, Pacritinib, Vernakalant, Fexinidazole, Benzonatate, Macimorelin, Dexmedetomidine, Pralsetinib, Adagrasib, Tebentafusp, Remdesivir, Ponesimod, and Voclosporin, for their association with QT prolongation and potential for Torsades de Pointes (TdP).

AZCERT maintains and regularly updates the QTdrugs List, a comprehensive database of medications associated with QT prolongation and potential heart rhythm disturbances, based on scientific evidence reviewed by its Scientific Review Committee through active and passive surveillance of data for thousands of prescription drugs.

AZCERT maintains and regularly updates a comprehensive QTdrugs List, identifying medicines with potential risks of causing heart rhythm disturbances (QT prolongation and TdP), based on scientific evidence reviewed by its Scientific Review Committee. This involves active and passive surveillance of thousands of prescription drugs.

Authors peer-reviewed publications in journals such as Nature Reviews of Cardiology and Annual Review of Pharmacology and Toxicology, and issues expert opinions on cardiovascular drug safety, drug regulation, and medication risks.

AZCERT authors and publishes articles and expert opinions on cardiovascular drug safety, drug regulation, and related topics in scientific journals and electronic publications to disseminate knowledge and inform clinical decision-making.

AZCERT authors and publishes articles and expert opinions on cardiovascular drug safety, drug regulation, and related topics in scientific journals and electronic publications.

Maintains and provides access to the QTdrugs List and related resources through the CredibleMeds.org website and mobile applications (iOS and Android), available in five languages, with visual icons indicating drug risk categories.

Allows users to create personal medication logs, submit questions to AZCERT’s founder Dr. Ray Woosley, and receive email notifications when the QTdrugs List is updated.

Provides three subscription tiers (Basic, Standard, Pro) for its CredibleMeds mobile app, offering increasing levels of functionality including drug safety information, advanced search, printable lists, alternative treatment options, and real-time alerts tailored to patients, families, and healthcare professionals.

Provides three mobile app plans: Basic (free access to essential drug safety information), Standard (enhanced features for patients and providers, including advanced search and printable lists), and Pro (comprehensive database and real-time alerts for clinical professionals and researchers).

Offers downloadable lists of over 190 medicines with potential heart rhythm risks and provides articles on medication safety that users can read and bookmark for future reference.

Offers email alerts to registered users when drug safety lists are updated and enables users to create personal medication logs and submit questions to AZCERT’s founder, Dr. Ray Woosley.

Offers free and subscription-based access to the QTdrugs List and related drug safety resources through the CredibleMeds website and mobile apps (iOS and Android), available in five languages. The platform includes risk category icons and tools for navigating medication risks.

AZCERT provides public access to the QTdrugs List and other medication safety information through its CredibleMeds website and mobile applications (Apple and Android), offering free and subscription-based versions with varying levels of detail and features, including alternative therapeutic options and real-time alerts.

AZCERT provides public access to the QTdrugs List and other medication safety information through its CredibleMeds website and mobile applications (Apple and Android), offering free and subscription-based versions with varying levels of detail and features, including risk categories, alternative therapeutic options, and real-time alerts.

AZCERT offers tools within its platforms that allow users to create personal medication logs and submit questions to experts like Dr. Ray Woosley for guidance on safe medication use.

AZCERT offers tools within its platform that allow users to create personal logs of their medications and submit questions to Dr. Ray Woosley for personalized guidance on safe medication use.

Provides downloadable lists of medications with potential heart rhythm risks, articles for public reading and bookmarking, and information on monoclonal antibody treatments and COVID-19 vaccines for high-risk populations.

Issues warnings about specific manufacturing lots of medicines recalled due to unacceptable levels of carcinogenic chemicals.

Published information on monoclonal antibody treatments for high-risk COVID-19 patients and provided guidance on COVID-19 vaccination for individuals with sudden arrhythmic death syndrome (SADS) conditions.

AZCERT provides articles and information on various medication safety topics, including specific guidance on COVID-19 treatments and vaccines for at-risk populations, and warnings about recalled medicines.

AZCERT provides information on broader medication safety topics, including articles about medication safety, warnings about recalled medicines, and guidance on COVID-19 treatments and vaccines for specific patient populations.

Issues warnings about specific manufacturing lots of medicines recalled due to unacceptable levels of carcinogenic chemicals, based on safety evaluations.